Sarcomas and the conservative management of uterine fibroids: a cause for concern?
The introduction of conservative management options has further increased the choices available to clinicians treating women with symptomatic uterine fibroids. However, in the absence of a tissue diagnosis, the possibility of mismanaging an underlying uterine sarcoma is still present, placing these patients at potential risk of a delayed diagnosis of this serious pathology. Evidence suggests that 1 in 250-400 women presenting with what are thought to be symptomatic fibroids, will in fact have an underlying sarcoma, making this an important clinical issue. This paper therefore reviews the methods currently available for the assessment of women in whom conservative management of symptomatic fibroids is contemplated.
Dover
R W
RW
Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia.
Ferrier
A J
AJ
Torode
H W
HW
D000328:Adult; D000792:Angiography; D001707:Biopsy, Needle; D003937:Diagnosis, Differential; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods; D008875:Middle Aged; D018570:Risk Assessment; D012509:Sarcoma / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D014463:Ultrasonography / Q000379:methods; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology
D007987:Gonadotropin-Releasing Hormone